GlassScriptPhysician profile
Robert Anthony Henning
NPI 1285736611
$6,751.08
in general payments reported to CMS, 2019-2025
26 companies · $1,478 in 2025
The $1,478 reported for 2025 was more than what 87% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $529 · 2022: $1,055 · 2023: $1,794 · 2024: $1,895 · 2025: $1,478.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,167.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $981.03 | 2021-2025 | Repatha, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $917.34 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $674.89 | 2021-2025 | Verquvo, Capvaxive |
| Novo Nordisk INC | $639.86 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Novartis Pharmaceuticals Corporation | $437.32 | 2021-2025 | |
| Boston Scientific Corporation | $430.23 | 2021-2025 | Watchman Flx, Cds - Mct/Cem Monitoring |
| Philips North America LLC | $326.59 | 2022-2025 | Extended Holter, (5091) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided |
| Pfizer INC. | $313.39 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $311.27 | 2021-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $262.45 | 2022-2025 | Farxiga |
| E.R. Squibb & Sons, L.L.C. | $261.24 | 2023-2024 | Camzyos, Eliquis |
| Sanofi-Aventis U.S. LLC | $167.09 | 2021-2023 | |
| Abbott Laboratories | $159.53 | 2021-2025 | Gallant, Aveir, Cardiomems |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $149.94 | 2021-2025 | Lifevest |
| Esperion Therapeutics, INC. | $144.14 | 2021-2025 | Nexletol |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $128.07 | 2023-2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.11 | 2021-2024 | Jardiance |
| Cvrx, INC. | $80.83 | 2024-2025 | Barostim Neo System |
| Kiniksa Pharmaceuticals International, Plc | $60.31 | 2024 | Arcalyst |
| Lexicon Pharmaceuticals, INC. | $51.54 | 2023 | Inpefa |
| Lilly USA, LLC | $33.87 | 2025 | Zepbound, Mounjaro |
| Scpharmaceuticals INC. | $24.66 | 2024 | |
| Medtronic, INC. | $21.22 | 2023 | Linq II |
| Amarin Pharma, INC. | $20.59 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $14.12 | 2024 | Evkeeza |
| Astellas Pharma US INC | $12.45 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Henning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.